Pemetrexed in second line and beyond small cell lung cancer

A hoosier oncology group phase II study

Shadia Jalal, Rafat Ansari, Ramaswamy Govindan, Sumeet Bhatia, Daniel Bruetman, William Fisher, Gregory Masters, Angela White, Daniel Stover, Menggang Yu, Nasser Hanna

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

INTRODUCTION: Small cell lung cancer (SCLC) is initially a chemotherapy-sensitive disease. Nevertheless, drug-resistance results in disease recurrence in most patients. Many drugs, including antimetabolites, are active, but only minimal progress has been made in improving survival times for those with advanced disease. Based on the need to discover better systemic therapies, we conducted a phase II study of pemetrexed in patients with relapsed SCLC. PATIENTS AND METHODS: Eligible patients had SCLC or poorly differentiated neuroendocrine cancers of the lung, Eastern Cooperative Oncology Group performance status of 0 to 2, and had received less than or equal to two prior chemotherapy regimens (additional targeted agents were allowed). Both chemotherapy-sensitive (relapse ≥90 days from completion of first line therapy) and chemotherapy-resistant (progressive disease during or within 90 days from completion of first line treatment) patients were eligible and analyzed separately. Pemetrexed was administered at 500 mg/m intravenously every 21 days for up to six cycles. All patients received folic acid, vitamin B12, and steroid prophylaxis. The primary objective of the trial was to estimate the clinical benefit rate (complete plus partial response plus stable disease) in each group. RESULTS: From January 2005 to September 2005, 20 patients were enrolled in the chemotherapy-sensitive arm and 23 patients in the chemotherapy-resistant arm. The majority of patients were men, the median age of the two groups were 62.5 and 65, respectively; 75% had a performance status of 0 or 1, and more than 50% had received more than one prior regimen. Grade 3/4 toxicities were as expected for pemetrexed. Progressive disease was the best response in 16 patients (80%) in the chemo-sensitive group and 19 patients (83%) in the chemo-refractory group. One patient had a partial response and three had stable disease in each group. CONCLUSION: Pemetrexed has minimal single agent activity in relapsed SCLC.

Original languageEnglish
Pages (from-to)93-96
Number of pages4
JournalJournal of Thoracic Oncology
Volume4
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

Pemetrexed
Small Cell Lung Carcinoma
Drug Therapy
Antimetabolites
Recurrence
Vitamin B 12

Keywords

  • Pemetrexed
  • Small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Pemetrexed in second line and beyond small cell lung cancer : A hoosier oncology group phase II study. / Jalal, Shadia; Ansari, Rafat; Govindan, Ramaswamy; Bhatia, Sumeet; Bruetman, Daniel; Fisher, William; Masters, Gregory; White, Angela; Stover, Daniel; Yu, Menggang; Hanna, Nasser.

In: Journal of Thoracic Oncology, Vol. 4, No. 1, 01.2009, p. 93-96.

Research output: Contribution to journalArticle

Jalal, S, Ansari, R, Govindan, R, Bhatia, S, Bruetman, D, Fisher, W, Masters, G, White, A, Stover, D, Yu, M & Hanna, N 2009, 'Pemetrexed in second line and beyond small cell lung cancer: A hoosier oncology group phase II study', Journal of Thoracic Oncology, vol. 4, no. 1, pp. 93-96. https://doi.org/10.1097/JTO.0b013e31818de1e6
Jalal, Shadia ; Ansari, Rafat ; Govindan, Ramaswamy ; Bhatia, Sumeet ; Bruetman, Daniel ; Fisher, William ; Masters, Gregory ; White, Angela ; Stover, Daniel ; Yu, Menggang ; Hanna, Nasser. / Pemetrexed in second line and beyond small cell lung cancer : A hoosier oncology group phase II study. In: Journal of Thoracic Oncology. 2009 ; Vol. 4, No. 1. pp. 93-96.
@article{a3e410859cb2405198ffa4e0a082de6a,
title = "Pemetrexed in second line and beyond small cell lung cancer: A hoosier oncology group phase II study",
abstract = "INTRODUCTION: Small cell lung cancer (SCLC) is initially a chemotherapy-sensitive disease. Nevertheless, drug-resistance results in disease recurrence in most patients. Many drugs, including antimetabolites, are active, but only minimal progress has been made in improving survival times for those with advanced disease. Based on the need to discover better systemic therapies, we conducted a phase II study of pemetrexed in patients with relapsed SCLC. PATIENTS AND METHODS: Eligible patients had SCLC or poorly differentiated neuroendocrine cancers of the lung, Eastern Cooperative Oncology Group performance status of 0 to 2, and had received less than or equal to two prior chemotherapy regimens (additional targeted agents were allowed). Both chemotherapy-sensitive (relapse ≥90 days from completion of first line therapy) and chemotherapy-resistant (progressive disease during or within 90 days from completion of first line treatment) patients were eligible and analyzed separately. Pemetrexed was administered at 500 mg/m intravenously every 21 days for up to six cycles. All patients received folic acid, vitamin B12, and steroid prophylaxis. The primary objective of the trial was to estimate the clinical benefit rate (complete plus partial response plus stable disease) in each group. RESULTS: From January 2005 to September 2005, 20 patients were enrolled in the chemotherapy-sensitive arm and 23 patients in the chemotherapy-resistant arm. The majority of patients were men, the median age of the two groups were 62.5 and 65, respectively; 75{\%} had a performance status of 0 or 1, and more than 50{\%} had received more than one prior regimen. Grade 3/4 toxicities were as expected for pemetrexed. Progressive disease was the best response in 16 patients (80{\%}) in the chemo-sensitive group and 19 patients (83{\%}) in the chemo-refractory group. One patient had a partial response and three had stable disease in each group. CONCLUSION: Pemetrexed has minimal single agent activity in relapsed SCLC.",
keywords = "Pemetrexed, Small cell lung cancer",
author = "Shadia Jalal and Rafat Ansari and Ramaswamy Govindan and Sumeet Bhatia and Daniel Bruetman and William Fisher and Gregory Masters and Angela White and Daniel Stover and Menggang Yu and Nasser Hanna",
year = "2009",
month = "1",
doi = "10.1097/JTO.0b013e31818de1e6",
language = "English",
volume = "4",
pages = "93--96",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "1",

}

TY - JOUR

T1 - Pemetrexed in second line and beyond small cell lung cancer

T2 - A hoosier oncology group phase II study

AU - Jalal, Shadia

AU - Ansari, Rafat

AU - Govindan, Ramaswamy

AU - Bhatia, Sumeet

AU - Bruetman, Daniel

AU - Fisher, William

AU - Masters, Gregory

AU - White, Angela

AU - Stover, Daniel

AU - Yu, Menggang

AU - Hanna, Nasser

PY - 2009/1

Y1 - 2009/1

N2 - INTRODUCTION: Small cell lung cancer (SCLC) is initially a chemotherapy-sensitive disease. Nevertheless, drug-resistance results in disease recurrence in most patients. Many drugs, including antimetabolites, are active, but only minimal progress has been made in improving survival times for those with advanced disease. Based on the need to discover better systemic therapies, we conducted a phase II study of pemetrexed in patients with relapsed SCLC. PATIENTS AND METHODS: Eligible patients had SCLC or poorly differentiated neuroendocrine cancers of the lung, Eastern Cooperative Oncology Group performance status of 0 to 2, and had received less than or equal to two prior chemotherapy regimens (additional targeted agents were allowed). Both chemotherapy-sensitive (relapse ≥90 days from completion of first line therapy) and chemotherapy-resistant (progressive disease during or within 90 days from completion of first line treatment) patients were eligible and analyzed separately. Pemetrexed was administered at 500 mg/m intravenously every 21 days for up to six cycles. All patients received folic acid, vitamin B12, and steroid prophylaxis. The primary objective of the trial was to estimate the clinical benefit rate (complete plus partial response plus stable disease) in each group. RESULTS: From January 2005 to September 2005, 20 patients were enrolled in the chemotherapy-sensitive arm and 23 patients in the chemotherapy-resistant arm. The majority of patients were men, the median age of the two groups were 62.5 and 65, respectively; 75% had a performance status of 0 or 1, and more than 50% had received more than one prior regimen. Grade 3/4 toxicities were as expected for pemetrexed. Progressive disease was the best response in 16 patients (80%) in the chemo-sensitive group and 19 patients (83%) in the chemo-refractory group. One patient had a partial response and three had stable disease in each group. CONCLUSION: Pemetrexed has minimal single agent activity in relapsed SCLC.

AB - INTRODUCTION: Small cell lung cancer (SCLC) is initially a chemotherapy-sensitive disease. Nevertheless, drug-resistance results in disease recurrence in most patients. Many drugs, including antimetabolites, are active, but only minimal progress has been made in improving survival times for those with advanced disease. Based on the need to discover better systemic therapies, we conducted a phase II study of pemetrexed in patients with relapsed SCLC. PATIENTS AND METHODS: Eligible patients had SCLC or poorly differentiated neuroendocrine cancers of the lung, Eastern Cooperative Oncology Group performance status of 0 to 2, and had received less than or equal to two prior chemotherapy regimens (additional targeted agents were allowed). Both chemotherapy-sensitive (relapse ≥90 days from completion of first line therapy) and chemotherapy-resistant (progressive disease during or within 90 days from completion of first line treatment) patients were eligible and analyzed separately. Pemetrexed was administered at 500 mg/m intravenously every 21 days for up to six cycles. All patients received folic acid, vitamin B12, and steroid prophylaxis. The primary objective of the trial was to estimate the clinical benefit rate (complete plus partial response plus stable disease) in each group. RESULTS: From January 2005 to September 2005, 20 patients were enrolled in the chemotherapy-sensitive arm and 23 patients in the chemotherapy-resistant arm. The majority of patients were men, the median age of the two groups were 62.5 and 65, respectively; 75% had a performance status of 0 or 1, and more than 50% had received more than one prior regimen. Grade 3/4 toxicities were as expected for pemetrexed. Progressive disease was the best response in 16 patients (80%) in the chemo-sensitive group and 19 patients (83%) in the chemo-refractory group. One patient had a partial response and three had stable disease in each group. CONCLUSION: Pemetrexed has minimal single agent activity in relapsed SCLC.

KW - Pemetrexed

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=61549083739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61549083739&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e31818de1e6

DO - 10.1097/JTO.0b013e31818de1e6

M3 - Article

VL - 4

SP - 93

EP - 96

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 1

ER -